David Platt
Vermögen: 623 756 $ am 31.05.2026
Vermögen: 623 756 $ am 31.05.2026
David Platt was the founder of International Gene Group, Inc., founded in 1992, serving as Chairman & Chief Executive Officer from 1992 to 2000.
Dr. Platt was the founder of SafeScience, Inc., founded in 1995, serving as Chairman & Chief Executive Officer in 2000.
Dr. Platt was the founder of Galectin Therapeutics, Inc., founded in 2001, serving as Chairman, President & Chief Executive Officer from 2001 to 2009.
Dr. Platt was the founder of Boston Therapeutics, Inc., founded in 2010, serving as Director from 2015 to 2016.
Dr. Platt is the founder of Oxygen Therapy, Inc., founded in 2016, serving as President.
Dr. Platt is currently Chairman, Chief Executive Officer & Secretary at BioXyTran, Inc. since 2018.
Former positions include Chairman, President & Chief Executive Officer at U.S.
Rare Earth Minerals, Inc.; Chairman, President, CEO, CFO & Treasurer at Avanyx Therapeutics, Inc.; Chairman & Chief Executive Officer at BioXyTran, Inc.; and Research Scientist-Internal Medicine at the University of Michigan in 1992.
Education includes a doctorate from The Hebrew University of Jerusalem, conferred in 1988.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOXYTRAN, INC. 46.2% | 03.04.2025 | 20’121’163 ( 46.2% ) | 623 756 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOXYTRAN, INC. | Vorstandsvorsitzender | 01.09.2018 |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-necrosis drugs | Gründer | 20.05.2016 |
| Unternehmen | Position | Ende |
|---|---|---|
| NANOMIX CORPORATION | Gründer | 08.06.2016 |
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets therapeutic drugs | Vorstandsvorsitzender | 30.11.2010 |
| GALECTIN THERAPEUTICS INC. | Vorstandsvorsitzender | 12.02.2009 |
SafeScience, Inc. | Vorstandsvorsitzender | 01.01.2000 |
International Gene Group, Inc. | Vorstandsvorsitzender | 01.01.2000 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Galectin Therapeutics, Inc.
Galectin Therapeutics, Inc. BiotechnologyHealth Technology Develops drugs to combat various diseases | Health Technology |
U.S. Rare Earth Minerals, Inc.
U.S. Rare Earth Minerals, Inc. Other Metals/MineralsNon-Energy Minerals Focus on the sale and distribution of certain products derived from its mining activities | Non-Energy Minerals |
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets therapeutic drugs | Health Technology |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SafeScience, Inc. | |
International Gene Group, Inc. | |
Boston Therapeutics, Inc.
Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures, and commercializes pharmaceutical products | Health Technology |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-necrosis drugs | Health Technology |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
BioXyTran, Inc.
BioXyTran, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that engages in the development, manufacture and commercialization of therapeutic drugs | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen